SOURCE: SciClone Pharmaceuticals, Inc.

April 16, 2008 06:30 ET

SciClone to Hold Symposium on New Therapies in Liver Cancer and Hepatitis C Virus

Three Leading Physicians to Present Data on Thymalfasin

FOSTER CITY, CA--(Marketwire - April 16, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will hold a symposium titled "New Therapies in Liver Cancer and Hepatitis" during the 43rd annual meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy. SciClone and Sigma-Tau will host the meeting on April 24, 2008, from 11:00 a.m. to 12:00 p.m. local time in Hall Yellow 1 in the Milan Convention Center.

Experts in the field of liver disease will discuss ZADAXIN®, generically referred to as thymalfasin or thymosin alpha 1, and its therapeutic benefits as a treatment for the hepatitis C virus (HCV) and liver cancer.

--  Enrico Garaci, M.D., Professor of Microbiology at the University of
    Rome "Tor Vergata" in Rome, Italy will present the immunomodulatory
    activities of thymalfasin against infectious agents.
    
--  Alessia Ciancio, M.D., Professor in the Department of Gastroenterology
    at the University of Torino in Torino, Italy will discuss the treatment of
    hepatitis C non-responders with pegylated interferon, ribavirin and
    thymalfasin.
    
--  Robert Gish, M.D., Medical Director of the Liver Disease Management
    and Transplantation Program at the California Pacific Medical Center in San
    Francisco will detail treatment of hepatocellular carcinoma (liver cancer)
    with TACE plus thymalfasin.
    

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of hepatitis C and malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese pharmaceutical market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate Contact:
    Erin Murphy
    SciClone Pharmaceuticals, Inc.
    (650) 358-3437
    Email Contact